Active Ingredient History

  • Now
Afimoxifene, also known as 4-hydroxytamoxifen (4-OHT) and by its tentative brand name TamoGel, is a selective estrogen receptor modulator (SERM) of the triphenylethylene group and an active metabolite of tamoxifen. The drug is under development under the tentative brand name TamoGel as a topical gel for the treatment of hyperplasia of the breast. It has completed a phase II clinical trial for cyclical mastalgia, but further studies are required before afimoxifene can be approved for this indication and marketed.   Wikipedia

  • SMILES: CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccc(O)cc3
  • Mol. Mass: 387.52
  • ALogP: 5.7
  • ChEMBL Molecule:
More Chemistry
4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol | 4,17 beta-dihydroxy-4-androstene-3-one | 4-androstene-7alpha-17beta-diol-3-one | 4-hydroxytamoxifen | 4-hydroxy-tamoxifen | 4'-hydroxytamoxifen | 4-hydroxytamoxifen, (e)-isomer | 4-hydroxytamoxifen, (z)-isomer | 4-monohydroxytamoxifen | 4-oht | 4oh-tamoxifen | 4-oht hydrotamoxifen | 7alpha-hydroxytestosterone | afimoxifene | androst-4-en-3-one, 4,17-dihydroxy-, (17beta)- | ici 79280 | para-hydroxytamoxifen | phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)- | phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, | tamogel | tamoxifen metabolite b


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue